| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5536375 | Vaccine | 2017 | 8 Pages |
Abstract
In comparison to no-vaccination, we found PCV13 use in those aged 65Â years was unlikely to be cost-effective unless the vaccine price was below A$46 or a longer duration of protection can be established. However, we found that in comparison to the PPV23, vaccination with PCV13 was cost-effective. This partly reflects the poor value for money estimated for PPV23 use in Australia.
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
S. Dirmesropian, J.G. Wood, C.R. MacIntyre, P. Beutels, P. McIntyre, R. Menzies, J.F. Reyes, C. Chen, A.T. Newall,